| 3.1 -0.16 (-4.91%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.37 |
1-year : | 4.84 |
| Resists | First : | 3.74 |
Second : | 4.15 |
| Pivot price | 3.42 |
|||
| Supports | First : | 3.09 |
Second : | 2.57 |
| MAs | MA(5) : | 3.26 |
MA(20) : | 3.56 |
| MA(100) : | 4.7 |
MA(250) : | 5.93 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 11.3 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 7.96 | Low : | 3.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MEIP ] has closed above bottom band by 16.9%. Bollinger Bands are 1.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.27 - 3.29 | 3.29 - 3.3 |
| Low: | 3.05 - 3.08 | 3.08 - 3.1 |
| Close: | 3.07 - 3.1 | 3.1 - 3.13 |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Thu, 18 Apr 2024
MEI Pharma, Inc. (MEIP) in Focus: Stock up 12.1% - Yahoo Movies Canada
Thu, 11 Apr 2024
MEI Pharma shelves second return of capital (NASDAQ:MEIP) - Seeking Alpha
Tue, 26 Mar 2024
MEI Pharma enrolls expansion cohort in leukemia study - Investing.com
Tue, 26 Mar 2024
Do Traders Think MEI Pharma Inc (MEIP) Can Turn Around Tuesday? - InvestorsObserver
Wed, 20 Mar 2024
VTRS: 3 Pharma Stocks Outperforming the Competition - StockNews.com
Fri, 08 Mar 2024
What is the Market's View on MEI Pharma Inc (MEIP) Stock's Price and Volume Trends Friday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 47.5 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | 2.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.93 |
| Profit Margin | 27.3 % |
| Operating Margin | 20.6 % |
| Return on Assets (ttm) | 8.3 % |
| Return on Equity (ttm) | 36.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 10.9 |
| EBITDA (p.s.) | 2.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 1.04 |
| PEG Ratio | -9.9 |
| Price to Book value | 0.34 |
| Price to Sales | 0.28 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|